195 related articles for article (PubMed ID: 31053766)
21. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
22. Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel.
Ando K; Sakamoto S; Takeshita N; Fujimoto A; Maimaiti M; Saito S; Sanjyon P; Imamura Y; Sato N; Komiya A; Akakura K; Ichikawa T
Prostate; 2020 Feb; 80(3):247-255. PubMed ID: 31816126
[TBL] [Abstract][Full Text] [Related]
23. Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Mostaghel EA; Marck BT; Kolokythas O; Chew F; Yu EY; Schweizer MT; Cheng HH; Kantoff PW; Balk SP; Taplin ME; Sharifi N; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2021 Nov; 27(21):6001-6011. PubMed ID: 34407973
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
[TBL] [Abstract][Full Text] [Related]
26. UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer.
Mahler M; Al-Ezzi E; Shrem NS; Zhang L; Winquist E; Canil C; Ong M; Hansen AR; Emmenegger U
Urol Oncol; 2022 Dec; 40(12):539.e17-539.e22. PubMed ID: 36272847
[TBL] [Abstract][Full Text] [Related]
27. The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
Rusarova N; Vitaskova D; Kalabova H; Ondruskova A; Purova D; Melichar B; Studentova H
Future Oncol; 2022 Dec; 18(38):4183-4192. PubMed ID: 36519589
[TBL] [Abstract][Full Text] [Related]
28. Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
Hiew K; Hart CA; Ali A; Elliott T; Ramani V; Sangar V; Lau M; Maddineni S; Brown M; Clarke N
Eur Urol Focus; 2019 Sep; 5(5):831-841. PubMed ID: 29699892
[TBL] [Abstract][Full Text] [Related]
29. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Halabi S; Lin CY; Small EJ; Armstrong AJ; Kaplan EB; Petrylak D; Sternberg CN; Shen L; Oudard S; de Bono J; Sartor O
J Natl Cancer Inst; 2013 Nov; 105(22):1729-37. PubMed ID: 24136890
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Jimbo M; Andrews JR; Ahmed ME; Dundar A; Karnes RJ; Bryce AH; Kendi AT; Kwon ED; Lowe VJ; Bold MS
Prostate; 2022 Jan; 82(1):41-48. PubMed ID: 34633087
[TBL] [Abstract][Full Text] [Related]
31. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
32. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
Fan L; Yang Y; Chi C; Ma X; Wang R; Gong Y; Zheng H; Pan J; Zhu Y; Dong B; Xue W
Prostate; 2019 May; 79(6):567-573. PubMed ID: 30614033
[TBL] [Abstract][Full Text] [Related]
34. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
Conteduca V; Wetterskog D; Castro E; Scarpi E; Romero-Laorden N; Gurioli G; Jayaram A; Lolli C; Schepisi G; Wingate A; Casadei C; Lozano R; Brighi N; Aragón IM; Marin-Aguilera M; Gonzalez-Billalabeitia E; Mellado B; Olmos D; Attard G; De Giorgi U
Eur J Cancer; 2021 Jul; 152():49-59. PubMed ID: 34077818
[TBL] [Abstract][Full Text] [Related]
35. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
36. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
37. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
38. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
40. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]